ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
15 May 2021 07:43

Asia Shorts: Sunny Optic, CMB, Ping An, 7&I, Keihan, Celltrion, Shinpoong, KCC, China Steel, Novatek

The Insight looks at large short interest movements across HK, Japan, Korea and Taiwan stocks and highlights large increases/decreases in shorts to...

Logo
347 Views
Share
03 May 2021 15:34

Hong Kong Connect Flows: Meituan, Wuxi Biologics, Anta Inflows Before May Golden Week

Of the top stocks measured by inflows last week, we highlight inflows into Meituan (3690 HK), Wuxi Biologics (Cayman) Inc. (2269 HK), and Anta...

Logo
199 Views
Share
bullishWuxi Biologics
26 Apr 2021 18:52

Wuxi Biologics Placement - Market Is Likely Well-Positioned for the Selldown

Wuxi Biologics Holdings is looking to raise up to US$1.3bn by selling about 2.3% of Wuxi Biologics (2269 HK). This is the company's 14th placement...

Share
17 Apr 2021 06:10

Asia Short Interest: Meituan, WuxiBio, Tencent, Nexon, Orix, Toshiba, Shiseido, Samsung, Hannstar

The Insight looks at large short interest movements across HK, Japan, Korea and Taiwan stocks and highlights large increases/decreases in shorts to...

Logo
349 Views
Share
13 Apr 2021 08:52

Presentation on Apr.12: 2021 High Conviction Ideas - Topchoice Medical (600763.CH)

This article analyzed Top Choice in terms of the 2020 and 2021Q1 financial results, market potential, business model, financial position compared...

Logo
363 Views
Share
x